Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1999, for Bioanalytical Systems, Inc. (Note: The input metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc.). The Company manufactures scientific instruments for trace organic compound determination and provides laboratory services, consulting, and research. The fiscal year ends September 30.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1999 | Nine Months Ended June 30, 1999 |
|---|---|---|
| Total Revenue | $4,973,000 | $14,628,000 |
| Net Income | $67,000 | $261,000 |
| Diluted EPS | $0.01 | $0.06 |
| Gross Margin | 45.8% | 47.2% |
| Operating Cash Flow (9mo) | $202,000 | |
| Cash and Equivalents | $1,860,000 (as of June 30, 1999) | |
| Total Debt | $4,716,000 ($477k current + $4,239k long-term) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 10.0% year-over-year for both the three-month and nine-month periods. This was driven by a significant increase in services revenue (up ~$600k for the quarter and ~$2.3M for the nine months) due to a UK services unit acquired in July 1998.
- Product Revenue Decline: Product revenue decreased slightly (to $2.4M for the quarter and $7.0M for the nine months) primarily due to reduced sales in Asia caused by currency fluctuations.
- Profitability Compression: Net income for the nine months dropped 53.1% to $261,000 from $557,000 in the prior year. Operating income for the nine months fell 45.9% to $486,000.
- Cost Increases: Cost of revenue increased 34.1% for the nine months, largely due to the UK acquisition and increased staffing levels. Cost of services revenue as a percentage of revenue rose to 65.8% (from 56.4% previously).
- Expense Management: Selling expenses decreased 9.8% due to reduced distributor commissions, and R&D expenses decreased 12.6% due to the expiration of grant projects. However, General and Administrative expenses increased 18.8% due to Y2K remediation efforts and enhanced vacation policies.
Guidance, Outlook, Risks, and Unusual Items
- Capital Expenditures: The Company spent $2.86 million on capital expenditures for the nine months ended June 30, 1999, primarily for facility construction and laboratory equipment. Management anticipates decreased capital expenditure levels for the remainder of fiscal 1999.
- Debt Financing: On June 24, 1999, the Company secured a $3.5 million commercial mortgage with a 5-year term and a balloon payment at maturity. Interest is charged at LIBOR + 200 basis points. The Company also maintains unused working capital and acquisition lines of credit totaling $7.5 million.
- Year 2000 (Y2K): Management expects Y2K remediation to be substantially complete by the end of summer 1999, with estimated capital expenditures under $100,000. The aggregate cost is not expected to be material.
- Legal Proceedings: The Company is defending a patent infringement lawsuit filed by CMA Microdialysis Holding A.B. regarding microdialysis probes. The product in question accounts for less than 1% of revenue. Management believes the outcome will not have a material adverse effect, though legal expenses may impact earnings.
- Acquisition Activity: On August 12, 1999, the Company announced a non-binding letter of intent to acquire Toxicology Pathology Services, Inc., pending review.
Investor Verification Checklist
- Verify the sustainability of the 10% revenue growth given the decline in product sales in Asia.
- Monitor the impact of the new $3.5 million mortgage on future interest expenses and cash flow.
- Assess the integration and profitability timeline of the UK services unit acquired in July 1998.
- Review the status of the CMA Microdialysis patent litigation and associated legal costs.
- Confirm the completion and cost of Y2K remediation projects as projected by management.
- Track the progress of the potential acquisition of Toxicology Pathology Services, Inc.